Search Within

Alexander Noor Shoushtari

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (22)
  2. Meeting Abstract (10)
  3. Research Letter (4)
Groups
  1. Department of Medicine (36)
  2. GSK Faculty (36)
  3. Hematologic Malignancies, Division of (36)
  4. Human Oncology and Pathogenesis Program (36)
  5. Melanoma Disease Management Team (36)
  6. Melanoma and Immunotherapeutics Service (36)

More Groups

People
  1. Michael Berger (13)
  2. Michael Postow (13)
  3. Ping Chi (13)
  4. Marc Ladanyi (11)
  5. Nikolaus Schultz (11)
  6. David Solit (10)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (1)
  4. 2022 (4)
  5. 2021 (5)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Clinical Cancer Research (5)
  3. Cancer Research (3)
  4. Nature Genetics (3)
  5. JCO Precision Oncology (2)
  6. Modern Pathology (2)

More Publications

Publishers
  1. American Association for Cancer Research (8)
  2. American Society of Clinical Oncology (8)
  3. Nature Publishing Group (7)
  4. American Medical Association (2)
  5. Cell Press (2)
  6. Nature Research (2)

More Publishers

Results (36)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
    Journal Article

    Kelly, C. M.; Shoushtari, A. N.; Qin, L. X.; D’Angelo, S. P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Mcfadyen, C.; Sjoberg, A.; Singer, S.; more...
    Investigational New Drugs (2019)

    Fulltext@MSK | Save
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Shoushtari, A. N.; Armenia, J.; Arora, A.; Rojas-Zamalloa, J.; Warner, A. B.; Derr, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Coit, D. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multigene sequencing, copy number alteration detection, and survival with first-line PD-1 based therapy in patients with mucosal melanoma
    Meeting Abstract

    Gottesdiener, L. S.; Gormally, M.; Armenia, J.; El-Jalby, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Wolchok, J. D.; Chapman, P. B.; Schultz, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Rates of ERBB2 alterations across melanoma subtypes and a complete response to trastuzumab emtansine in an ERBB2-amplified acral melanoma
    Journal Article

    Gottesdiener, L. S.; O'Connor, S.; Busam, K. J.; Won, H.; Solit, D. B.; Hyman, D. M.; Shoushtari, A. N.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • GNA11 Q209L mouse model reveals RasGRP3 as an essential signaling node in uveal melanoma
    Journal Article

    Moore, A. R.; Ran, L.; Guan, Y.; Sher, J. J.; Hitchman, T. D.; Zhang, J. Q.; Hwang, C.; Walzak, E. G.; Shoushtari, A. N.; Monette, S.; more...
    Cell Reports (2018)

    Fulltext@MSK | Save
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Clinical and morphologic characteristics of MEK inhibitor - Associated retinopathy: Differences from central serous chorioretinopathy
    Journal Article

    Francis, J. H.; Habib, L. A.; Abramson, D. H.; Yannuzzi, L. A.; Heinemann, M.; Gounder, M. M.; Grisham, R. N.; Postow, M. A.; Shoushtari, A. N.; Chi, P.; more...
    Ophthalmology (2017)

    Fulltext@MSK | Save
  • Patient perspectives on ipilimumab across the melanoma treatment trajectory
    Journal Article

    Shuk, E.; Shoushtari, A. N.; Luke, J.; Postow, M. A.; Callahan, M.; Harding, J. J.; Roth, K. G.; Flavin, M.; Granobles, A.; Christian, J.; more...
    Supportive Care in Cancer (2017)

    Fulltext@MSK | Save